Why You Are Not Losing Weight on GLP-1 Medications?

dr-syra-glp1-clinic-banner-713x338

You’re not losing weight on GLP-1 medications because of insufficient treatment time, low starting doses, missed medication, calorie intake, type 2 diabetes, weight-promoting prescriptions, or a weaker response to treatment. Weight loss also slows when your body needs fewer calories after losing weight.

Ozempic and Wegovy contain semaglutide, while Mounjaro and Zepbound contain tirzepatide. Semaglutide activates GLP-1 receptors, while tirzepatide activates both GIP and GLP-1 receptors. The medications have different dosing schedules, FDA-approved indications, and weight-loss outcomes.

When weight loss remains limited after several months of treatment, your prescribed dose, medication history, HbA1c, and weight changes help identify the cause. Dr. Syra Hanif, MD, evaluates these factors through physician-led treatment at a weight loss clinic in NYC.

What May Be Affecting Your GLP-1 Weight Loss?

Answer five questions to review possible factors affecting your progress.

Question 1 of 520%
1. Which GLP-1 medication are you taking?






2. How long have you been taking it?





3. What best describes your weight changes?





4. Which statement best describes your treatment?





5. Which factors are relevant to you? (Select all that apply)







Your selections are processed in your browser. This assessment does not submit your answers.

What Are the Top Reasons You Are Not Losing Weight on GLP-1 Medications?

The ten main reasons you’re not losing weight on GLP-1 medications are insufficient treatment time, low medication doses, missed doses, excess calorie intake, low physical activity, type 2 diabetes, side effects, weight-promoting medications or medical conditions, weight-loss plateaus, and inadequate biological response.

  • You’re Still Early in GLP-1 Treatment
  • You’re Taking a Low GLP-1 Dose
  • You’re Missing Doses or Interrupting Treatment
  • You’re Consuming More Calories Than You Realize
  • You’re Not Getting Enough Physical Activity
  • You Have Type 2 Diabetes
  • You’re Experiencing GLP-1 Side Effects
  • You Have Other Medical Conditions or Take Weight-Promoting Medications
  • You’ve Hit a Weight-Loss Plateau
  • You May Be a GLP-1 Slow Responder or Nonresponder

1. You’re Still Early in GLP-1 Treatment

Insufficient treatment time is a common reason for limited early weight loss because semaglutide and tirzepatide begin at lower doses. The starting doses help your body tolerate treatment before dose escalation.

Injectable Wegovy starts at 0.25 mg weekly, while Zepbound starts at 2.5 mg weekly. Both increase gradually according to their prescribing schedules. Appetite reduction can begin before noticeable changes appear on the scale, particularly during the first month.

The time semaglutide takes to produce weight loss also differs between the initiation and maintenance phases. Four weeks of treatment at a starting dose does not provide the same information as several months at a prescribed maintenance dose.

What to consider: Check your treatment start date and dose-escalation schedule. Four weeks at 0.25 mg injectable Wegovy or 2.5 mg Zepbound represents treatment initiation, not a completed trial of maintenance treatment.

2. You’re Taking a Low GLP-1 Dose

A low starting dose can limit weight loss because GLP-1 medications use gradual dose increases to reduce gastrointestinal side effects. Higher maintenance doses provide different medication exposure, but dose escalation depends on treatment response and tolerability.

Injectable Wegovy usually progresses from 0.25 mg to 0.5 mg, 1 mg, and 1.7 mg before reaching 2.4 mg weekly. Under the June 2026 FDA label, eligible adults who tolerate 2.4 mg for at least four weeks and need further weight reduction can receive up to 7.2 mg weekly when prescribed. Zepbound begins at 2.5 mg weekly and increases in 2.5 mg steps, with approved weight-management maintenance doses of 5 mg, 10 mg, or 15 mg.

Semaglutide and tirzepatide doses cannot be compared milligram for milligram. Their different receptor activity and approved treatment regimens make direct dose equivalence inappropriate.

What to consider: Confirm whether you’re receiving an initiation or maintenance dose. Your prescriber assesses the approved dose range, side effects, and weight-loss response before changing the regimen. Do not increase the dose independently.

3. You’re Missing Doses or Interrupting Treatment

Missed injections and treatment interruptions reduce consistent medication exposure. Delayed refills, incorrect administration, and extended gaps between doses can make weight-loss results difficult to assess.

Ozempic allows a missed injection within five days of its scheduled date. Mounjaro and Zepbound allow a missed injection within four days. Injectable Wegovy has different missed-dose instructions, while oral Wegovy follows a daily schedule.

Injection accuracy also matters. The FDA has reported serious dosing errors involving compounded semaglutide when people confuse milligrams, milliliters, and syringe units. Incorrect dosing can cause significant nausea, vomiting, and other adverse effects.

What to consider: Review your medication schedule and any missed injections or tablets. Follow the instructions for your specific product. Contact your prescriber about restarting after a prolonged interruption, particularly when your previous dose caused gastrointestinal symptoms.

4. You’re Consuming More Calories Than You Realize

Reduced appetite does not always produce weight loss because calorie intake can still equal your body’s energy requirements. Semaglutide and tirzepatide increase fullness and reduce hunger, but food portions, beverages, and meal choices continue to affect body weight.

Cooking oils, butter, creamy sauces, sweetened coffee drinks, and alcoholic beverages add calories without always producing lasting fullness. Frequent snacks also contribute to total intake. For example, one tablespoon of olive oil contains approximately 120 calories, even when the meal itself appears small.

Your calorie requirements generally decrease after weight loss because a lighter body uses less energy during daily activities. Reviewing portions, added fats, beverages, and snacks provides a more accurate picture of your eating patterns than judging calorie intake by appetite alone.

5. You’re Not Getting Enough Physical Activity

Low physical activity reduces daily calorie expenditure and can slow weight loss during semaglutide or tirzepatide treatment. Spending more time sitting, walking fewer steps, or stopping regular exercise decreases the energy your body uses.

Fatigue, nausea, joint pain, and work schedules can reduce movement. Resistance training also becomes important during weight reduction because losing body weight involves changes in both fat mass and lean tissue. Strength exercises help preserve muscle and physical function.

The CDC recommends at least 150 minutes of moderate-intensity aerobic activity weekly and muscle-strengthening activities on two or more days for most adults. Walking, cycling, swimming, and resistance exercise provide different ways to work toward these targets according to your health and mobility.

6. You Have Type 2 Diabetes

Type 2 diabetes is associated with lower average weight reduction in some semaglutide trials than studies involving people without diabetes. Differences in treatment regimens, other prescriptions, and clinical characteristics also affect the results.

In the STEP 1 trial, adults with overweight or obesity without diabetes taking injectable semaglutide 2.4 mg weekly lost an average of 14.9% of their starting weight over 68 weeks. In STEP 2, adults with overweight or obesity and type 2 diabetes taking the same weekly dose lost an average of 9.6%. The trials involved different populations, so diabetes alone does not explain the full difference.

Ozempic and Mounjaro can also lower HbA1c without producing the weight reduction you expect. Insulin and sulfonylureas such as glipizide and glimepiride can contribute to weight gain while improving blood glucose control.

What to consider: Compare your HbA1c and weight-loss results separately. Review insulin, glipizide, or glimepiride with your diabetes clinician before making medication changes, since adjustments can affect blood sugar and hypoglycemia risk.

7. You’re Experiencing GLP-1 Side Effects

GLP-1 side effects interfere with weight-loss treatment when nausea, vomiting, diarrhea, or constipation affects medication use and dose escalation. Persistent symptoms also make hydration and balanced eating more difficult.

Semaglutide and tirzepatide affect appetite regulation and gastrointestinal function. Constipation can temporarily increase scale weight through retained stool, while repeated vomiting can cause dehydration and treatment interruptions.

Persistent nausea, constipation, and delayed gastric emptying are among the long-term side effects of semaglutide that require medical assessment when symptoms continue or become severe. Nausea does not prove that medication is working, and the absence of nausea does not indicate treatment failure.

What to consider: Record when symptoms occur and whether they interfere with eating, hydration, or medication use. Severe or persistent abdominal pain, repeated vomiting, or dehydration requires prompt medical attention rather than another dose increase.

8. You Have Other Medical Conditions or Take Weight-Promoting Medications

Hypothyroidism, Cushing syndrome, obstructive sleep apnea, and medications such as prednisone, olanzapine, and insulin can complicate weight loss during GLP-1 treatment. Each affects weight regulation through a different process.

Medical condition or medicationHow it affects weight
HypothyroidismContributes to fatigue, constipation, and modest weight gain, partly through fluid retention
Cushing syndromeCauses characteristic changes in fat distribution and muscle weakness
Obstructive sleep apneaDisrupts sleep and contributes to fatigue that limits physical activity
PrednisoneIncreases appetite and can cause fluid retention
Olanzapine and clozapineAre associated with increased appetite, weight gain, and metabolic changes
MirtazapineCan increase appetite and body weight
Insulin, glipizide, and glimepirideCan contribute to weight gain despite improving blood glucose

A medication-related weight change becomes easier to identify when your weight history is compared with prescription start dates and dose changes. For example, new weight gain after starting prednisone requires a different assessment from persistent weight gain accompanied by cold intolerance and constipation.

Your clinician determines whether medication review or targeted testing is appropriate. Do not stop insulin, psychiatric medication, or prescribed corticosteroids without medical supervision.

9. You’ve Hit a Weight-Loss Plateau

A weight-loss plateau occurs when body weight stabilizes after previous reduction. Your body generally needs fewer calories at a lower weight, so the calorie deficit that supported earlier weight loss becomes smaller.

Daily activity, food intake, and body composition also affect further progress. Constipation, menstrual-cycle changes, increased sodium intake, and fluid retention can temporarily hide changes in body fat. A few days of unchanged weight do not establish a sustained plateau.

A 2025 analysis of the SURMOUNT-1 trial found that the median time to a defined weight plateau during tirzepatide treatment ranged from approximately 24 to 36 weeks across baseline BMI categories. The researchers used consecutive 12-week weight-change intervals, not daily scale readings, to assess plateau timing.

Proposed clinical perspective for Dr. Syra Hanif, MD, subject to her approval:

“When weight loss stops during GLP-1 treatment, the dose alone does not explain the plateau. Reviewing the weight trend, medication history, calorie intake, and physical activity helps identify whether the treatment plan needs adjustment.”

What to consider: Compare your weight measurements over several weeks under similar conditions. A sustained plateau after losing 15 pounds requires a different clinical review from no weight loss during the first month of treatment.

10. You May Be a GLP-1 Slow Responder or Nonresponder

Some people lose less weight than others despite taking the same GLP-1 medication. Differences in medication exposure, treatment duration, tolerability, and individual biological response affect results.

A slow responder experiences limited early weight loss but achieves meaningful reduction later. Persistently inadequate response means weight loss remains below the individualized treatment goal after an appropriate treatment trial.

In a 2025 post hoc analysis of SURMOUNT-1, 278 of 1,545 included tirzepatide-treated participants lost less than 5% of their starting weight by week 12. Among those 278 participants, 194 reached at least 5% weight reduction by week 24, and 250 reached that threshold by week 72.

The study specifically followed selected tirzepatide-treated participants who received at least 75% of assigned doses and had the required follow-up measurements. Its late-response percentages do not establish the expected outcome for every person taking semaglutide or tirzepatide.

Why You Are Not Losing Weight on Ozempic, Wegovy, Mounjaro, or Zepbound

Limited weight loss on Ozempic, Wegovy, Mounjaro, and Zepbound has different medication-specific causes because the products contain semaglutide or tirzepatide and follow different dosing schedules. Ozempic and Mounjaro primarily treat type 2 diabetes, while Wegovy and Zepbound have specific weight-management indications.

Semaglutide activates GLP-1 receptors, while tirzepatide activates GIP and GLP-1 receptors. Clinical trials also include different participant populations and doses. A comparison of GLP-1 medications for weight loss must therefore account for diabetes status, prescribed regimens, and treatment duration rather than comparing unrelated trial averages.

Why You Are Not Losing Weight on Ozempic

Limited weight loss on Ozempic can result from its 0.25 mg initiation dose, missed injections, weight-promoting diabetes medications, or a weaker response to semaglutide after reaching a prescribed maintenance dose.

Ozempic starts at 0.25 mg weekly for four weeks before increasing to 0.5 mg. Its approved maintenance doses include 0.5 mg, 1 mg, and 2 mg weekly, depending on the clinical indication. Ozempic is approved for type 2 diabetes and specific cardiovascular and kidney risk-reduction indications, not chronic weight management.

Insulin, glipizide, and glimepiride can contribute to weight gain even when Ozempic improves HbA1c. The lack of weight loss on Ozempic after several months at a prescribed maintenance dose requires reviewing those medications, missed injections, calorie intake, and changes in body weight rather than judging response from the first four weeks.

Why You Are Not Losing Weight on Wegovy

Limited weight loss on Wegovy can result from incomplete dose escalation, interrupted treatment, incorrect tablet administration, or a lower-than-expected response to semaglutide.

Wegovy is available in injectable and oral formulations. Injectable Wegovy begins at 0.25 mg weekly. Its recommended adult maintenance dose for weight reduction is generally 2.4 mg weekly, with 1.7 mg as another approved maintenance option. The updated FDA label also permits an increase to 7.2 mg weekly for eligible adults after tolerating 2.4 mg for at least four weeks when additional weight reduction is clinically indicated.

Oral Wegovy uses a separate daily dosing schedule. The tablet is taken in the morning on an empty stomach with no more than 4 fluid ounces of water. Eating, drinking, or taking other oral medications within the following 30 minutes can reduce semaglutide absorption.

Incorrect oral administration and insufficient exposure to the prescribed maintenance regimen require different corrections. Someone taking the tablet with breakfast has a different administration problem from someone receiving weekly injections consistently but experiencing inadequate weight reduction.

Why You Are Not Losing Weight on Mounjaro

Limited weight loss on Mounjaro can reflect its 2.5 mg initiation dose, type 2 diabetes, concurrent insulin or sulfonylurea treatment, and individual response to tirzepatide.

Mounjaro begins at 2.5 mg weekly for four weeks before increasing to 5 mg. Further dose escalation depends on blood glucose control, tolerability, and clinical needs, up to the approved maximum of 15 mg weekly.

Insulin and glimepiride can contribute to weight gain while Mounjaro improves HbA1c. Blood glucose improvement therefore does not guarantee an equivalent decrease in body weight. Your prescriber assesses glycemic control, medication exposure, and weight history as separate treatment outcomes.

Why You Are Not Losing Weight on Zepbound

Limited early weight loss on Zepbound can occur during dose escalation, after interrupted treatment, or when the response to tirzepatide develops later than expected.

Zepbound begins at 2.5 mg weekly for four weeks before increasing to 5 mg. Its approved weight-management maintenance doses are 5 mg, 10 mg, and 15 mg weekly. Dose changes depend on the prescribing schedule and treatment tolerability.

The 2025 SURMOUNT-1 late-responder analysis found that 70% of selected participants with less than 5% weight reduction at week 12 reached at least 5% by week 24. The proportion increased to 90% by week 72. Early limited response during tirzepatide treatment does not automatically establish long-term treatment failure.

How Long Does It Take You to Lose Weight on GLP-1 Medications?

Measurable weight loss can begin within the first several weeks of GLP-1 treatment, while larger reductions generally develop over several months. The timeline depends on medication, dose escalation, maintenance treatment, and individual response.

The four commonly prescribed injectable medications begin at different doses.

MedicationInitial weekly doseFirst scheduled increaseTypical maintenance dosing
Ozempic0.25 mg0.5 mg after 4 weeks0.5, 1, or 2 mg
Wegovy injection0.25 mg0.5 mg after 4 weeksUsually 1.7 or 2.4 mg; 7.2 mg for selected eligible adults
Mounjaro2.5 mg5 mg after 4 weeks5, 7.5, 10, 12.5, or 15 mg
Zepbound2.5 mg5 mg after 4 weeks5, 10, or 15 mg for weight management

The table covers injectable formulations. Oral Wegovy has a separate daily dosing schedule. Maintenance dose selection follows the approved indication and prescribing information.

Your treatment stage affects how the results are interpreted. Four weeks on an initiation dose does not represent the same medication exposure as several months of maintenance therapy. Continued weight measurements, dose history, and tolerability establish whether weight reduction is developing as expected.

Why Your Weight Loss Plateaus on GLP-1 Medications

Your weight loss plateaus on GLP-1 treatment when calorie intake approaches the energy your body requires at its lower weight. Semaglutide and tirzepatide continue to affect appetite during treatment, but losing body mass reduces the energy required for daily activity and weight maintenance.

The 2025 SURMOUNT-1 plateau analysis found different plateau timelines across BMI groups during tirzepatide treatment. Researchers defined weight stabilization through repeated measurements across 12-week periods, which separates a sustained plateau from normal fluctuations.

Your weight trend provides the clinical context. A temporary increase after a salty meal, constipation, or menstrual-cycle changes differs from several weeks of unchanged weight. A sustained plateau requires reviewing current food intake, activity, medication exposure, and previous weight loss rather than assuming the prescription has stopped working.

Why Are Some People Slow Responders to GLP-1 Medications?

Some people respond slowly to GLP-1 medications because meaningful weight reduction develops at different rates. Early slow response and persistently inadequate response describe different treatment patterns.

AttributeEarly slow responsePersistently inadequate response
Initial weight lossLimitedLimited
Subsequent weight lossReaches a meaningful threshold in some peopleRemains below the treatment goal
Medication exposureCan include dose escalationRequires assessment after adequate exposure
Clinical approachContinue evaluation and monitoringReview adherence, suitability, and alternatives

A four-week weight measurement does not establish permanent nonresponse. Your prescribed medication, treatment duration, maintenance-dose history, and weight trend determine whether further observation or treatment reassessment is appropriate.

The 2025 SURMOUNT-1 late-responder analysis describes a selected tirzepatide population. It does not provide a universal nonresponse threshold for Ozempic, Wegovy, or other GLP-1 products.

What Should You Do If You’re Not Losing Weight on GLP-1 Medications?

To address limited weight loss on GLP-1 medications, first confirm your prescribed dose, medication consistency, food intake, physical activity, and weight trend. A treatment review also identifies weight-promoting prescriptions and medical conditions that affect progress.

  1. Check your medication and treatment stage. Confirm whether you’re taking semaglutide or tirzepatide and whether you’re receiving an initiation or maintenance dose.
  2. Review missed doses and administration. Check injection dates, refill interruptions, and oral Wegovy administration instructions when applicable.
  3. Compare consistent weight measurements. Distinguish early limited weight loss from a sustained plateau after previous progress.
  4. Review food and beverage intake. Include cooking oils, snacks, sugary drinks, alcohol, and meal portions rather than estimating calories from appetite alone.
  5. Assess walking and resistance exercise. Identify changes in movement and strength training since starting medication.
  6. Review prescriptions and relevant symptoms. Insulin, glipizide, prednisone, olanzapine, and mirtazapine can affect body weight.
  7. Discuss persistent inadequate response with your prescriber. Dose adjustments, further testing, and alternative medications require assessment of treatment benefits and risks.

Do not increase your dose, combine semaglutide with another GLP-1 medication, or restart a previously prescribed higher dose after a prolonged interruption without medical guidance.

When Should You See a Doctor If You’re Not Losing Weight on GLP-1?

You should see a doctor when weight loss remains below your treatment goal after an adequate period of consistent therapy, when weight loss stops after earlier progress, or when side effects prevent regular medication use.

A medication review is particularly appropriate when weight remains stable despite maintenance treatment, weight increases without an obvious explanation, or blood glucose remains above target. Persistent nausea, vomiting, diarrhea, and constipation also warrant assessment when symptoms affect hydration, nutrition, or treatment adherence.

Severe or persistent abdominal pain, especially with vomiting, requires prompt medical attention because pancreatitis is a serious potential adverse reaction. Repeated vomiting with dehydration also requires urgent care. Difficulty breathing or swelling of the face or throat requires emergency medical assistance.

How Does Dr. Syra Hanif Evaluate Inadequate GLP-1 Weight Loss?

Dr. Syra Hanif, MD, evaluates inadequate GLP-1 weight loss by reviewing your medication history, weight changes, diabetes status, medical conditions, and treatment tolerability. She is a board-certified family medicine physician and Medical Director of Dr. Syra Aesthetics in Manhattan.

A medical weight-loss consultation includes your prescribed medication, current dose, treatment duration, missed doses, previous weight-loss attempts, nutrition, physical activity, and relevant prescriptions. Your medical history and symptoms also determine whether thyroid testing or other laboratory investigations are appropriate.

Dr. Hanif’s physician-led medical weight-loss program includes individualized treatment planning and ongoing monitoring. Treatment decisions account for diabetes control, medication side effects, weight-related conditions, and previous response rather than assuming every weight-loss plateau requires a higher dose.

Dr. Syra Aesthetics provides in-person consultations in Manhattan and telehealth evaluations for eligible individuals across New York.

Not Losing Weight on GLP-1 Medication?

Dr. Syra Hanif, MD, provides medical evaluations for inadequate GLP-1 response, persistent weight-loss plateaus, and related metabolic concerns.

Schedule a Weight-Loss Consultation

Frequently Asked Questions

Can GLP-1 Medications Improve Your Blood Sugar Without Weight Loss?

Yes. Ozempic and Mounjaro can improve HbA1c without substantial weight reduction. Blood glucose control and weight loss are separate treatment outcomes, especially when insulin or sulfonylureas also affect body weight.

Does a Lack of Nausea Mean Your GLP-1 Medication Is Not Working?

No. Nausea is a possible medication side effect, not a measure of effectiveness. Semaglutide and tirzepatide can reduce weight or improve blood glucose without causing nausea.

Can Constipation Make It Seem Like Your GLP-1 Medication Is Not Working?

Yes. Constipation temporarily affects scale weight through retained stool. Persistent constipation with severe abdominal pain, vomiting, or abdominal swelling requires medical evaluation.

Can You Lose Inches Without Losing Pounds on GLP-1 Medication?

Yes. Waist circumference can decrease while total body weight remains similar because body composition, fluid balance, and digestive contents affect the measurements differently.

Can GLP-1 Medications Become Less Effective Over Time?

Weight loss can slow during continued semaglutide or tirzepatide treatment as your energy requirements decline. Slower weight reduction does not automatically mean the medication has stopped regulating appetite.

Can You Switch GLP-1 Medications If You’re Not Losing Weight?

A clinician can consider another treatment when weight loss remains inadequate after an appropriate trial. Ozempic, Wegovy, Mounjaro, and Zepbound have different approved indications and dosing schedules. Switching requires a medication-specific assessment rather than combining GLP-1 treatments.

Medical information is intended for educational purposes and does not replace individualized medical advice. Prescription medication decisions require evaluation by a qualified healthcare professional.

Written & Medically Reviewed by

Dr. Syra Hanif, M.D.
Board-Certified Primary Care Physician

Dr. Syra Hanif, M.D., is a board-certified physician specializing in aesthetic medicine, longevity, and preventative wellness. As Medical Director of Dr. Syra Aesthetics & Longevity Institute in NYC, she focuses on aesthetics, healthy aging, and overall wellness.

Read More

Schedule a Consultation

Latest Blog Posts

why-am-i-not-losing-weight-on-ozempic-featured-713x338

Why Am I Not Losing Weight on Ozempic?

You’re not losing weight on Ozempic for several reasons, including an insufficient treatment dose, consuming more calories than your body...

dr-syra-glp1-clinic-banner-713x338

Why You Are Not Losing Weight on GLP-1 Medications?

You’re not losing weight on GLP-1 medications because of insufficient treatment time, low starting doses, missed medication, calorie intake, type...

semaglutide-featured-final

How Long Does It Take for Semaglutide to Work?

Semaglutide starts acting after the first dose, but appetite changes often become noticeable during the first days or weeks, while...